Multi-cancer early detection, or MCED, tests are growing in awareness and adoption worldwide.

The idea is compelling: a blood test that looks for cancer-related signals across multiple cancer types, including some cancers without routine screening options.

The need to bridge these screening gaps is real.

Traditional screening programmes focus on a limited number of cancers, such as breast, colorectal, cervical, and lung cancer in selected groups. Yet many cancer deaths occur in cancers that do not have guideline-recommended screening pathways. In fact, a recent U.S. analysis found that approximately 83% of annual cancer deaths were not covered by existing screening programmes. [1]

This is where MCED testing may add value.

However, MCED is also a complex and fast-developing field. Terms such as “cancer types,” “organ systems,” “subtypes,” “sensitivity,” “specificity,” and “tissue of origin” are not just technical details. They shape what an MCED result can and cannot mean.

So how should patients and physicians read MCED claims clearly?

Here are three common misconceptions, and three questions that can help patients and physicians have a more informed conversation.

Misconception 1: A Bigger Cancer Count Always Means A Broader Test

One of the first numbers people notice in an MCED test is the number of cancers it claims to cover.

But that number is not always straightforward.

A test may say it screens for 10 major cancer types. Another may refer to hundreds of cancer subtypes. At first glance, hundreds of subtypes may sound broader than 10. But these figures often count different things.

A “cancer type” typically refers to a broad clinical category, such as lung cancer, colorectal cancer, liver-biliary cancer, or head and neck cancer. A “subtype” may refer to a more specific classification within those categories, such as an anatomical site, histological subtype, or molecular subtype.

For example, lung cancer is commonly divided into small cell lung cancer and non-small cell lung cancer, with non-small cell lung cancer further including subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Liver and bile duct cancers include distinct but anatomically related malignancies such as hepatocellular carcinoma and cholangiocarcinoma. Counting each subsite or subtype is not the same as counting separate, independently validated screening categories. The National Cancer Institute recognises over 200 types of cancers and virtually limitless amount of subtypes. [2]

Consequently, cancer count alone is not always the best way to compare tests. A test that includes fewer, higher-burden cancers may cover a meaningful proportion of cancer incidence or mortality. A test that lists many rare subtypes may sound broader, but the clinical impact depends on how common those cancers are, how deadly they are, and how well the test performs for each category.

The question is not only:

It should be:

Misconception 2: MCED Tests Detect All Cancers Equally Well

MCED tests are designed to look for cancer-related signals in blood, but they do not detect every cancer type, stage, or tumor biology with the same accuracy.

Performance heavily depends on how well a test distinguishes biological signal from background noise. Different MCED tests may also look for different biological signals including cancer-associated mutations, viral nucleic acids, DNA methylation patterns, fragmentation profiles, chromosomal changes, protein or immune markers, or combinations of these signals. [3,4]

A mutation-based approach must detect tumor-derived mutations in blood while distinguishing them from background signals, including clonal hematopoiesis. [5] A methylation-based approach may help predict tissue of origin, but methylation patterns can also be influenced by biological factors such as aging, inflammation, and other non-cancer processes. [6,7] Protein markers may add useful information, but they can also be affected by benign conditions, inflammation, or non-cancer disease.

This is why no single headline number tells the full story.

In general, many blood-based cancer detection approaches perform better when tumor burden is higher. Detection is often stronger in later-stage disease than in very early-stage disease.

In one clinical validation study of a targeted methylation-based MCED test, overall sensitivity was 51.5%. Sensitivity increased with cancer stage: 16.8% for stage I, 40.4% for stage II, 77.0% for stage III, and 90.1% for stage IV cancers. [8]

Some cancers may also be biologically harder to detect through blood-based cfDNA approaches. Central nervous system tumors can be challenging because tumor-derived DNA may be less readily detectable in peripheral blood, partly due to the blood-brain barrier. [9] For urinary tract cancers such as bladder cancer, urine-based biomarkers are also being studied because urine may provide a more direct sample source than blood. [10,11]

None of this makes MCED testing less meaningful. It simply means that performance must always be interpreted in context.

Misconception 3: MCED Testing Replaces The Usual Screening And Diagnostic Pathway

MCED tests are screening tools, not diagnostic tests. They are designed to detect cancer-related signals that may indicate the need for further evaluation. Some tests can also suggest where in the body the signal is most likely coming from.

But a positive MCED result is not a definitive cancer diagnosis.

Cancer is complex. A blood-based signal needs to be interpreted alongside a person’s symptoms, medical history, risk factors, imaging findings, and, where needed, tissue diagnosis.

Depending on the suspected cancer type, follow-up may include physical examination, imaging, endoscopy, repeat testing, specialist review, or biopsy. In the PATHFINDER study, participants with a cancer signal detected underwent diagnostic workup, most commonly imaging, before a diagnosis was confirmed or ruled out. [12]

MCED can help sound the alarm, but diagnostic evaluation is still needed to confirm what is present.

Crucially, MCED also does not replace established cancer screening methods. Mammograms, cervical screening with Pap smear or HPV testing, colorectal cancer screening, and low-dose CT for eligible lung cancer screening remain important because they are supported by specific evidence, guidelines, and follow-up pathways. [13,14]

Some standard screening methods also do more than detect cancer. They may detect pre-cancerous changes before invasive cancer develops, such as colonoscopy for colorectal cancer or cervical screening for HPV-related disease. A blood test cannot substitute for that preventative capability.

MCED may add value, especially for cancers without routine population screening options. But it must sit within a broader screening strategy, guided by age, sex, symptoms, family history, personal risk factors, and physician assessment.

What MCED Still Needs To Show

Finding cancer earlier can be valuable, especially when it leads to timely diagnosis and effective treatment.

But MCED still need to show whether earlier detection translates into longer, healthier lives. Studies are actively evaluating these "liquid biopsies" to ensure they meaningfully reduce cancer-related mortality without causing overtreatment or harmful false positives.

In the DETECT-A study, blood testing combined with PET-CT detected cancers in women without a prior cancer history, including some cancers without routine screening options. [15] The study supported the feasibility of integrating a multi-cancer blood test into care, but longer-term outcome evidence is still needed to show whether this approach reduces cancer mortality.

The National Cancer Institute also notes that potential harms of multi-cancer detection testing may include false negatives, false positives, overdiagnosis, overtreatment, and the possibility that earlier detection of some cancers may not change treatment options or survival. [14]

As MCED advances, we are gaining clarity on who benefits most, where testing fits best, and how to handle the results.

Three Questions To Ask At Your Next Check-Up

MCED testing is not defined by a headline number alone.

Cancer counts need context. Performance varies by cancer type, stage, and biological signal. Positive results need diagnostic confirmation. Negative results should be interpreted alongside symptoms, risk factors, and recommended screening.

If you are considering MCED testing, three questions can make the conversation more useful:

1. What does this test count?  Ask whether the number refers to cancer types, organ systems, anatomical sites, or subtypes, and what proportion of cancer incidence or mortality is covered.

2. How does this test perform?  Ask what biological signal the test measures, how sensitivity varies by cancer type and stage, and what is known about false positive and false negative results.

3. What happens next?  Ask how the result fits with your age, sex, family history, symptoms, and recommended screening plan, and what follow-up would be needed after a positive result.

As MCED technology continues to develop, clear communication will matter as much as innovation.

The goal is not simply to detect more cancers. It is to help patients and physicians make better-informed decisions about screening, follow-up, and care.

References

1. Matrana MR, et al. Nat Commun. 2025;16:8456.

2. National Cancer Institute. Cancer Types. National Cancer Institute. Accessed July 9, 2026. 

3. Hoffman RM, et al. Cancer. 2025;131:e35823.

4. Brito-Rocha T, Martins-Figueiredo M, Jeronimo C, Henrique R. Cells. 2023;12(6):935.

5. Abbosh C, Swanton C, Birkbak NJ. Ann Oncol. 2019;30(3):358-359.

6. Salameh Y, Bejaoui Y, El Hajj N. Front Genet. 2020;11:171.

7. Li SJ, et al. Epigenomics. 2024;16(9):653-666.

8. Klein EA, et al. Ann Oncol. 2021;32(9):1167-1177.

9. McEwen AE, Leary SES, Lockwood CM. Front Cell Dev Biol. 2020;8:45.

10. Salfer B, Tahbaz N, Subramaniam S, et al. Front Mol Biosci. 2022;9:1073467.

11. Huang FF, Li Y, Wang Y, et al. Front Bioeng Biotechnol. 2024;12:1458362.

12. Schrag D, et al. Lancet. 2023;402(10409):1251-1260.

13. American Cancer Society. Multi-cancer detection tests. Updated October 2, 2025. Accessed June 2026.

14. National Cancer Institute. Questions and answers about multi-cancer detection tests. Division of Cancer Prevention. Accessed June 2026.

15. Lennon AM, et al. Science. 2020;369(6499):eabb9601.